-
Target Oncol: Real-world exploration of the efficacy of Crizotinib in patients with ROS1-positive advanced non-small cell lung cancer (NSCLC)
Time of Update: 2022-03-04
Therefore, a team from the United States conducted a relevant real-world study to evaluate the efficacy of Crizotinib (crizotinib) in patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) .
-
【News】Lolatinib for the treatment of ROS1-positive advanced NSCLC clinical trial approved in China
Time of Update: 2022-01-09
CStone Pharmaceuticals announced on January 4 that the clinical trial application (IND) of loratinib for ROS1-positive advanced non-small cell lung cancer (NSCLC) has been approved by the National Medical Products Administration (NMPA) of China .
-
of lorlatinib for ROS1-positive advanced NSCLC is about to open tumor information
Time of Update: 2021-06-30
/6 inhibitor approved clinical new drug: lorlatinib for ROS1-positive advanced lung cancer related research in China is about to open 01JCO: neoadjuvant DOS chemotherapy can improve patients with resectable advanced gastric cancer PFSPRODIGY is a neoadjuvant chemotherapy (docetaxel + oxa A phase III randomized study of Liplatin+S-1) (DOS)+Surgery+Auxiliary S-1 vs.
-
Study announces preliminary results of taletrectinib treatment of ROS1 fusion-positive NSCLC trial
Time of Update: 2021-06-16
The poster titled at the ASCO annual meeting is "Preliminary results of the TRUST study: taletrectinib is used in the Phase 2 clinical trial of ROS1 fusion-positive non-small cell lung cancer patients .
-
JCO: Entratinib is safe and effective in the treatment of locally advanced or metastatic ROS1
Time of Update: 2021-03-20
Therefore, researchers have a new idea to extend the follow-up time and confirm in a larger population that Entratinib can be used in patients with locally advanced or metastatic ROS proto-oncogene 1 (ROS1) fusion-positive non-small cell lung cancer (including baseline The effectiveness and safety of patients with central transfer?This study included adult patients with locally advanced or metastatic ROS1 fusion-positive NSCLC, with or without CNS metastasis.
-
Repotrectinib was again awarded the breakthrough therapy title for the treatment of ROS1-positive metastasis NSCLC
Time of Update: 2021-01-16
Turning Point Therapeutics Inc. announced on December 8 that its candidate drug for ROS1-positive metastasis non-small cell lung cancer (NSCLC), which has not been treated with ROS1 tyrosine kinase inhibitors (TKI-naïve), has been named a breakthrough treatment by the U.S. Food and Drug Administration (FDA).
-
Repotrectinib was again awarded the breakthrough therapy title for the treatment of ROS1-positive metastasis NSCLC
Time of Update: 2020-12-11
On December 8, Turning Point Therapeutics Inc. announced that its candidate drug, reporctrectinib, for the treatment of ROS1-positive metastasis non-small cell lung cancer (NSCLC), which has not been treated with ROS1 tyrosine kinase inhibitors (TKI-naïve), has been named a breakthrough therapy by the U.S. Food and Drug Administration (FDA).
-
Clini Cancer Research: Second generation ROS1-TKI, repotrectinib, anti-tumor activity of NSCLC for primary treatment or ROS1 mutation
Time of Update: 2020-07-14
Objective: Although the treatment of first-line keratosin has benefited patients with ROS1 and lung cancer, the incidence of ROS1-G2032R (ROS1G2032R) mutation and the progress of the central nervous